NASDAQ:OPTN

OptiNose Stock Forecast, Price & News

$4.29

-0.16 (-3.60 %)

(As of 01/26/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.27

Now: $4.29▼

$4.49

50-Day Range

$4.06

MA: $4.30▼

$4.73

52-Week Range

$3.14

Now: $4.29▼

$10.00

Volume388,371 shs

Average Volume387,429 shs

Market Capitalization$223.43 million

P/E RatioN/A

Dividend YieldN/A

Beta1.03

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.

MarketRank^™

Overall MarketRank^™

1.61 out of 5 stars

Medical Sector

299th out of 1,925 stocks

Pharmaceutical Preparations Industry

152nd out of 773 stocks

3.3 Analyst's Opinion

Consensus Rating
OptiNose has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.00, OptiNose has a forecasted upside of 342.9% from its current price of $4.29.
Amount of Analyst Coverage
OptiNose has received no research coverage in the past 90 days.

2.4 Community Rank

Outperform Votes
OptiNose has received 226 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
OptiNose has received 246 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
OptiNose has received 52.12% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote “Outperform” if you believe OPTN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
OptiNose does not currently pay a dividend.
Dividend Growth
OptiNose does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OptiNose insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $688,312.00 in company stock.
Percentage Held by Insiders
38.00% of the stock of OptiNose is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
62.93% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for OptiNose are expected to grow in the coming year, from ($2.07) to ($1.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OptiNose is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OptiNose is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OptiNose has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:OPTN

Previous Symbol

CUSIPN/A

CIK1494650

Webwww.optinose.com

Phone267-364-3500

Employees221

Year FoundedN/A

Debt

Debt-to-Equity Ratio3.79

Current Ratio3.98

Quick Ratio3.76

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$34.63 million

Price / Sales6.45

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.48 per share

Price / Book2.90

Profitability

EPS (Most Recent Fiscal Year)($2.63)

Net Income$-110,050,000.00

Net Margins-230.14%

Return on Equity-294.64%

Return on Assets-59.29%

Miscellaneous

Outstanding Shares52,081,000

Market Cap$223.43 million

Next Earnings Date3/4/2021 (Estimated)

OptionableNot Optionable

$4.29

-0.16 (-3.60 %)

(As of 01/26/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive OPTN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.

OptiNose (NASDAQ:OPTN) Frequently Asked Questions

How has OptiNose's stock been impacted by Coronavirus (COVID-19)?

OptiNose's stock was trading at $5.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OPTN stock has decreased by 15.2% and is now trading at $4.29.
View which stocks have been most impacted by COVID-19.

Is OptiNose a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OptiNose stock.
View analyst ratings for OptiNose or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than OptiNose?

Wall Street analysts have given OptiNose a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OptiNose wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is OptiNose's next earnings date?

OptiNose is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for OptiNose.

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.13. The company earned $15.44 million during the quarter, compared to analysts' expectations of $15.40 million. OptiNose had a negative trailing twelve-month return on equity of 294.64% and a negative net margin of 230.14%.
View OptiNose's earnings history.

What price target have analysts set for OPTN?

3 Wall Street analysts have issued 1 year price objectives for OptiNose's stock. Their forecasts range from $17.00 to $21.00. On average, they expect OptiNose's stock price to reach $19.00 in the next year. This suggests a possible upside of 342.9% from the stock's current price.
View analysts' price targets for OptiNose or view Wall Street analyst' top-rated stocks.

Who are some of OptiNose's key competitors?

Some companies that are related to OptiNose include Protagonist Therapeutics (PTGX), Esperion Therapeutics (ESPR), Phibro Animal Health (PAHC), MannKind (MNKD), Syndax Pharmaceuticals (SNDX), Dyne Therapeutics (DYN), Odonate Therapeutics (ODT), Collegium Pharmaceutical (COLL), Avid Bioservices (CDMO), Provention Bio (PRVB), G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), Gossamer Bio (GOSS), VBI Vaccines (VBIV) and ZIOPHARM Oncology (ZIOP).
View all of OPTN's competitors.

What other stocks do shareholders of OptiNose own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX).

Who are OptiNose's key executives?

OptiNose's management team includes the following people:

Mr. Peter K. Miller, CEO & Director (Age 59, Pay $1.02M)
Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 55, Pay $743.72k)
Mr. Keith Alan Goldan, Chief Financial Officer (Age 49, Pay $603.73k)
Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 44, Pay $708.26k)
Mr. Jonathan Neely, VP of Investor Relations & Bus. Operations
Ms. Karen E. Brophy, VP of HR (Age 57)
Mr. John Messina, Sr. VP of Clinical Devel. & Medical Affairs
Mr. Victor M. Clavelli, Chief Commercial Officer (Age 47)
Ms. Helena Kyttari Djupesland, Co-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway)

When did OptiNose IPO?

(OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

Who are OptiNose's major shareholders?

OptiNose's stock is owned by a variety of retail and institutional investors. Top institutional investors include Paradigm Capital Management Inc. NY (4.80%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Keith A Goldan, Michael F Marino III, Peter K Miller, Ramy A Mahmoud and Thomas Edward Gibbs.
View institutional ownership trends for OptiNose.

Which institutional investors are buying OptiNose stock?

OPTN stock was acquired by a variety of institutional investors in the last quarter, including Paradigm Capital Management Inc. NY. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Keith A Goldan, and Michael F Marino III.
View insider buying and selling activity for OptiNose or or view top insider-buying stocks.

How do I buy shares of OptiNose?

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $4.29.

How big of a company is OptiNose?

OptiNose has a market capitalization of $223.43 million and generates $34.63 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. OptiNose employs 221 workers across the globe.

What is OptiNose's official website?

The official website for OptiNose is www.optinose.com.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here